Genmab A/S
CSE:GMAB
Genmab A/S
Total Liabilities & Equity
Genmab A/S
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Genmab A/S
CSE:GMAB
|
Total Liabilities & Equity
kr45.8B
|
CAGR 3-Years
23%
|
CAGR 5-Years
25%
|
CAGR 10-Years
32%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Total Liabilities & Equity
kr9.5B
|
CAGR 3-Years
66%
|
CAGR 5-Years
43%
|
CAGR 10-Years
32%
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Total Liabilities & Equity
€1.2B
|
CAGR 3-Years
3%
|
CAGR 5-Years
12%
|
CAGR 10-Years
35%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Total Liabilities & Equity
kr14.4B
|
CAGR 3-Years
6%
|
CAGR 5-Years
15%
|
CAGR 10-Years
23%
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Total Liabilities & Equity
kr96m
|
CAGR 3-Years
6%
|
CAGR 5-Years
18%
|
CAGR 10-Years
10%
|
|
|
Saniona AB
STO:SANION
|
Total Liabilities & Equity
kr339.7m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
29%
|
CAGR 10-Years
36%
|
|
Genmab A/S
Glance View
In the world of biotechnology, Genmab A/S has carved a niche as a leader in the development and innovation of antibody therapeutics. Established in Denmark in 1999, the company has focused on harnessing the power of antibodies to create novel treatments for cancer and other serious diseases. Genmab's approach is both scientific and strategic, leveraging its proprietary DuoBody and HexaBody platforms to engineer antibodies that are designed to enhance effectiveness and reduce side effects. This innovative focus has not only set Genmab apart as a pioneer in immunotherapy but has also yielded a rich pipeline of products, several of which have gained regulatory approval and found a place in global markets. Genmab's business model is built on a foundation of collaboration and strategic partnerships with major pharmaceutical companies, including heavyweights such as Janssen and Roche. These alliances are crucial as they provide the financial support needed for large-scale clinical trials and access to global distribution networks. Revenue streams primarily flow from milestone payments, licensing fees, and royalties generated from successful therapies. The company's notable blockbuster, Darzalex, a treatment for multiple myeloma, continues to be a significant revenue driver, exemplifying Genmab's capacity to transform scientific discovery into economic success. Through this blend of innovation, strategic partnerships, and commercialization, Genmab maintains a robust business while keeping its dedication to pioneering treatments at the forefront of its mission.
See Also
What is Genmab A/S's Total Liabilities & Equity?
Total Liabilities & Equity
45.8B
DKK
Based on the financial report for Dec 31, 2024, Genmab A/S's Total Liabilities & Equity amounts to 45.8B DKK.
What is Genmab A/S's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
32%
Over the last year, the Total Liabilities & Equity growth was 30%. The average annual Total Liabilities & Equity growth rates for Genmab A/S have been 23% over the past three years , 25% over the past five years , and 32% over the past ten years .
You don't have any saved screeners yet